

Table 1. Summary of EARS-Net data by pathogen and year
(data correct as of 13/08/2025)

National Data						% Trends, 2020-2024	
Pathogen	Year					Sparkline	Significance
	2020	2021	2022	2023	2024		
Number laboratories by year-end	37	36	36	35	33		
%Coverage of population	100%	98%	97%	96%	82%		
<i>E. coli</i>							
Number of isolates	3032	3073	3181	3312	3004		
%Ampicillin-R*	65.2%	63.0%	62.1%	62.9%	63.7%		-
%Amoxicillin-clavulanic acid-R*	49.1%	48.7%	45.1%	47.7%	47.2%		-
%Piperacillin/tazobactam-R*	13.2%	12.5%	11.6%	12.7%	12.9%		-
%Cefoxitin-R*	6.5%	4.6%	4.8%	4.8%	5.8%		-
%3GC-R*	11.9%	10.3%	9.7%	10.3%	11.7%		-
%Cefotaxime/ceftriaxone-R*	11.2%	9.1%	10.0%	9.9%	11.4%		-
%Ceftazidime-R*	10.8%	10.0%	8.3%	8.8%	10.5%		-
%ESBL-producers*	9.9%	7.8%	9.1%	8.7%	9.9%		-
%Ciprofloxacin-R*	18.8%	16.1%	15.7%	15.8%	15.0%		-
%Gentamicin-R*	9.3%	8.8%	7.7%	7.7%	8.3%		-
%Gentamicin/Amikacin/Tobramycin-R*	10.8%	10.0%	9.1%	9.0%	9.6%		-
%Carbapenem†-R*	0.3%	0.1%	0.3%	0.1%	0.1%		-
Number Carbapenemase-producers	3	0	4	3	5		
%MDR*	4.8%	4.2%	3.7%	3.3%	3.9%		-
<i>S. aureus</i>							
Number of isolates	1081	1262	1250	1307	1103		
Number Meticillin-R (or MRSA)	126	138	132	126	118		
%Meticillin-R (or MRSA)	11.7%	10.9%	10.6%	9.6%	10.7%		-
<i>K. pneumoniae</i>							
Number of isolates	512	515	492	636	511		
%Ampicillin-R*	99.2%	99.8%	100.0%	99.4%	98.8%		-
%Amoxicillin-clavulanic acid-R*	32.2%	32.5%	29.3%	33.8%	29.7%		-
%Piperacillin/tazobactam-R*	20.5%	21.3%	21.9%	24.6%	21.5%		-
%Cefoxitin-R*	6.5%	5.8%	5.7%	8.3%	9.1%		-
%3GC-R*	18.4%	15.5%	13.2%	15.6%	14.8%		-
%Cefotaxime/ceftriaxone-R*	16.9%	14.9%	11.2%	13.9%	13.4%		-
%Ceftazidime-R*	18.4%	16.1%	12.8%	14.9%	13.8%		-
%ESBL-producers*	14.3%	14.4%	10.8%	12.3%	10.6%		-
%Ciprofloxacin-R*	17.0%	16.2%	9.6%	15.7%	9.6%		-
%Gentamicin-R*	9.1%	9.3%	7.3%	8.5%	4.8%		-
%Gentamicin/Amikacin/Tobramycin-R*	11.8%	11.1%	7.5%	9.0%	5.9%		↓
%Carbapenem†-R*	1.8%	2.0%	1.2%	1.4%	1.2%		-
Number Carbapenemase-producers	5	8	5	10	6		
%MDR*	7.9%	8.0%	3.3%	5.6%	2.8%		-
<i>E. faecium</i>							
Number of isolates	499	619	634	639	523		
%Vancomycin-R (VREfm)	35.7%	27.2%	27.8%	21.4%	21.8%		↓
%Ampicillin-R*	95.4%	94.8%	96.6%	96.0%	94.3%		-
%HLG-R*	59.2%	60.2%	60.8%	62.2%	65.9%		↑
%Linezolid-R*	1.1%	0.3%	0.6%	0.2%	0.6%		-
%MDR*	25.3%	18.1%	17.2%	16.9%	14.2%		↓
<i>E. faecalis</i>							
Number of isolates	330	365	375	389	300		
%Vancomycin-R (VREfa)	0.9%	0.3%	1.3%	0.5%	0.3%		-
%Ampicillin-R*	0.9%	0.8%	1.1%	0.5%	0.7%		-
%HLG-R*	16.0%	16.7%	16.4%	17.2%	11.9%		-
%Linezolid-R*	0.0%	0.6%	0.0%	0.3%	0.4%		-

* Not all isolates tested; † Carbapenems include imipenem, meropenem and ertapenem

Number of isolates presented in bold; proportions (%) presented in *italics*

R, Resistant; MRSA, Methicillin-Resistant *S. aureus*; VREfm, Vancomycin-Resistant *E. faecium*

MRSA, Methicillin-Resistant *S. aureus*; VREfm, Vancomycin-Resistant *E. faecium*

HLG, High-Level Gentamicin; 3GC, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime)

ESBL, Extended-Spectrum Beta-Lactamase; MDR, Multi-Drug Resistant (see definition for each pathogen)

↓ ↑ indicate significant downward and upward trends

Table 1 (continued). Summary of EARS-Net data by pathogen and year
(data correct as of **13/08/2025**)

Pathogen	National Data					% Trends, 2020-2024	
	2020	2021	2022	2023	2024	Sparkline	Significance
Number laboratories by year-end	37	36	36	35	33		
%Coverage of population	100%	98%	97%	96%	82%		Not all tested
<i>S. pneumoniae</i>							
Number of isolates	189	179	305	361	369		
of which notified to public health	179	172	293	346	355		
Number serotyped	170	154	276	335	330		
% serotyped	89.9%	86.0%	90.5%	92.8%	89.4%		
Number Penicillin-Non-WT	32	34	72	61	76		
%Penicillin-Non-WT*	16.9%	19.0%	23.6%	17.4%	20.8%		-
of which: %R	0.0%	1.1%	2.0%	1.7%	2.7%		↑
%I	16.9%	17.9%	21.6%	15.2%	17.9%		-
%Erythromycin-R*	13.2%	12.2%	16.5%	14.1%	12.9%		-
%Penicillin-NWT/Erythromycin-R*	9.4%	6.9%	10.7%	8.1%	8.7%		-
<i>P. aeruginosa</i>							
Number of isolates	271	294	319	297	269		
%Piperacillin/tazobactam-R*	13.0%	14.6%	9.9%	10.9%	5.3%		-
%Ceftazidime-R*	10.5%	10.7%	9.1%	6.6%	4.1%		↓
%Imipenem/meropenem-R*	7.5%	7.8%	8.2%	6.4%	5.2%		-
%Ciprofloxacin-R*	14.7%	9.6%	8.6%	8.0%	7.5%		-
%Tobramycin-R*	2.4%	3.5%	2.1%	0.8%	1.7%		-
%MDR*	2.1%	6.4%	4.8%	3.4%	1.2%		-
<i>Acinetobacter</i> spp.							
Number of isolates	53	73	80	71	59		
%Ciprofloxacin-R*	7.3%	3.1%	1.4%	1.4%	5.6%		-
%Gentamicin-R*	2.2%	3.1%	1.6%	0.0%	1.7%		-
%Gentamicin/Amikacin/Tobramycin-R*	2.2%	3.0%	1.5%	1.5%	1.7%		-
%Imipenem/meropenem-R*	0.0%	1.5%	2.5%	0.0%	0.0%		-
%MDR*	0.0%	0.0%	0.0%	0.0%	0.0%		-
TOTAL EARS-NET PATHOGENS	5967	6380	6636	7012	6138		
Group A streptococci							
Number of isolates	35	26	71	243	92		
of which notified to public health	32	24	71	243	90		
Number emm-typed	28	22	62	220	84		
% emm-typed	80.0%	84.6%	87.3%	90.5%	91.3%		
%Erythromycin-R*	17.1%	16.7%	9.2%	3.5%	9.4%		-
Group B streptococci							
Number of isolates	119	139	138	125	136		
%Erythromycin-R*	26.7%	41.9%	40.9%	41.4%	46.5%		-
Candida spp. (Yeasts)							
	Number of isolates						
<i>C. auris</i>	0	0	0	0	0		
<i>C. albicans</i>	85	125	129	136	98		
<i>C. glabrata</i>	53	78	84	81	56		
<i>C. parapsilosis</i>	57	51	49	59	40		
<i>C. dubliniensis</i>	5	10	4	9	6		
<i>C. tropicalis</i>	4	17	9	6	6		
<i>C. krusei</i>	0	6	1	6	0		
<i>C. lusitaniae</i>	5	2	4	5	0		
<i>C. metapsilosis</i>	0	0	1	4	3		
<i>C. fermentati</i>	0	0	0	2	0		
<i>C. duobushaemoloni</i>	0	0	0	2	0		
<i>C. guilliermondii</i>	1	1	3	1	0		
<i>C. lipolytica</i>	0	1	0	0	0		
<i>C. pelliculosa</i>	0	0	0	1	0		
<i>C. orthopsilosis</i>	0	1	0	1	1		
<i>Candida</i> spp. (unspecified)	11	0	1	0	1		
Total <i>Candida</i> spp	221	292	285	313	211		
TOTAL ALL PATHOGENS	6342	6837	7130	7693	6577		

* Not all isolates tested

Number of isolates presented in bold; proportions (%) presented in *italics*

R, Resistant; Non-WT, Non-Wild Type [includes isolates that are Susceptible, increased exposure (I) and Resistant (R)]

MDR, Multi-Drug Resistant (see definition for each pathogen; note: new definition for *P. aeruginosa*)

↓ ↑ indicate significant downward and upward trends; - indicates no trend